Clinical Trial Update: Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the investigational drug DNL747 for amyotrophic lateral sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• DNL747

Snippet

Sponsor: Sanofi | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: TERMINATED